Mesothelioma: Pleural, Version 1.2024

Featured Updates to the NCCN Guidelines

Authors:
James Stevenson Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute

Search for other papers by James Stevenson in
Current site
Google Scholar
PubMed
Close
 MD
,
David S. Ettinger The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Search for other papers by David S. Ettinger in
Current site
Google Scholar
PubMed
Close
 MD
,
Douglas E. Wood Fred Hutchinson Cancer Center

Search for other papers by Douglas E. Wood in
Current site
Google Scholar
PubMed
Close
 MD
,
Dara L. Aisner University of Colorado Cancer Center

Search for other papers by Dara L. Aisner in
Current site
Google Scholar
PubMed
Close
 MD, PhD
,
Wallace Akerley Huntsman Cancer Institute at the University of Utah

Search for other papers by Wallace Akerley in
Current site
Google Scholar
PubMed
Close
 MD
,
Jessica R. Bauman Fox Chase Cancer Center

Search for other papers by Jessica R. Bauman in
Current site
Google Scholar
PubMed
Close
 MD
,
Ankit Bharat Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Search for other papers by Ankit Bharat in
Current site
Google Scholar
PubMed
Close
 MD
,
Debora S. Bruno Case Comprehensive Cancer Center/ University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute

Search for other papers by Debora S. Bruno in
Current site
Google Scholar
PubMed
Close
 MD, MS
,
Joe Y. Chang The University of Texas MD Anderson Cancer Center

Search for other papers by Joe Y. Chang in
Current site
Google Scholar
PubMed
Close
 MD, PhD
,
Lucian R. Chirieac Dana-Farber/Brigham and Women’s Cancer Center

Search for other papers by Lucian R. Chirieac in
Current site
Google Scholar
PubMed
Close
 MD
,
Malcolm DeCamp University of Wisconsin Carbone Cancer Center

Search for other papers by Malcolm DeCamp in
Current site
Google Scholar
PubMed
Close
 MD
,
Aakash Desai O’Neal Comprehensive Cancer Center at UAB

Search for other papers by Aakash Desai in
Current site
Google Scholar
PubMed
Close
 MD, MPH
,
Thomas J. Dilling Moffitt Cancer Center

Search for other papers by Thomas J. Dilling in
Current site
Google Scholar
PubMed
Close
 MD, MS
,
Jonathan Dowell UT Southwestern Simmons Comprehensive Cancer Center

Search for other papers by Jonathan Dowell in
Current site
Google Scholar
PubMed
Close
 MD
,
Gregory A. Durm Indiana University Melvin and Bren Simon Comprehensive Cancer Center

Search for other papers by Gregory A. Durm in
Current site
Google Scholar
PubMed
Close
 MD, MS
,
Marina C. Garassino The UChicago Medicine Comprehensive Cancer Center

Search for other papers by Marina C. Garassino in
Current site
Google Scholar
PubMed
Close
 MD
,
Scott Gettinger Yale Cancer Center/Smilow Cancer Hospital

Search for other papers by Scott Gettinger in
Current site
Google Scholar
PubMed
Close
 MD
,
Travis E. Grotz Mayo Clinic Comprehensive Cancer Center

Search for other papers by Travis E. Grotz in
Current site
Google Scholar
PubMed
Close
 MD
,
Matthew A. Gubens UCSF Helen Diller Family Comprehensive Cancer Center

Search for other papers by Matthew A. Gubens in
Current site
Google Scholar
PubMed
Close
 MD, MS
,
Rudy P. Lackner Fred & Pamela Buffett Cancer Center

Search for other papers by Rudy P. Lackner in
Current site
Google Scholar
PubMed
Close
 MD
,
Michael Lanuti Mass General Cancer Center

Search for other papers by Michael Lanuti in
Current site
Google Scholar
PubMed
Close
 MD
,
Jules Lin University of Michigan Rogel Cancer Center

Search for other papers by Jules Lin in
Current site
Google Scholar
PubMed
Close
 MD
,
Billy W. Loo Jr Stanford Cancer Institute

Search for other papers by Billy W. Loo Jr in
Current site
Google Scholar
PubMed
Close
 MD, PhD
,
Christine M. Lovly Vanderbilt-Ingram Cancer Center

Search for other papers by Christine M. Lovly in
Current site
Google Scholar
PubMed
Close
 MD, PhD
,
Fabien Maldonado Vanderbilt-Ingram Cancer Center

Search for other papers by Fabien Maldonado in
Current site
Google Scholar
PubMed
Close
 MD
,
Erminia Massarelli City of Hope National Medical Center

Search for other papers by Erminia Massarelli in
Current site
Google Scholar
PubMed
Close
 MD, PhD, MS
,
Daniel Morgensztern Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

Search for other papers by Daniel Morgensztern in
Current site
Google Scholar
PubMed
Close
 MD
,
Trey C. Mullikin Duke Cancer Institute

Search for other papers by Trey C. Mullikin in
Current site
Google Scholar
PubMed
Close
 MD
,
Thomas Ng The University of Tennessee Health Science Center

Search for other papers by Thomas Ng in
Current site
Google Scholar
PubMed
Close
 MD
,
Gregory A. Otterson The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

Search for other papers by Gregory A. Otterson in
Current site
Google Scholar
PubMed
Close
 MD
,
Dawn Owen Mayo Clinic Comprehensive Cancer Center

Search for other papers by Dawn Owen in
Current site
Google Scholar
PubMed
Close
 MD, PhD
,
Sandip P. Patel UC San Diego Moores Cancer Center

Search for other papers by Sandip P. Patel in
Current site
Google Scholar
PubMed
Close
 MD
,
Tejas Patil University of Colorado Cancer Center

Search for other papers by Tejas Patil in
Current site
Google Scholar
PubMed
Close
 MD
,
Patricio M. Polanco UT Southwestern Simmons Comprehensive Cancer Center

Search for other papers by Patricio M. Polanco in
Current site
Google Scholar
PubMed
Close
 MD
,
Gregory J. Riely Memorial Sloan Kettering Cancer Center

Search for other papers by Gregory J. Riely in
Current site
Google Scholar
PubMed
Close
 MD, PhD
,
Jonathan Riess UC Davis Comprehensive Cancer Center

Search for other papers by Jonathan Riess in
Current site
Google Scholar
PubMed
Close
 MD
,
Theresa A. Shapiro The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Search for other papers by Theresa A. Shapiro in
Current site
Google Scholar
PubMed
Close
 MD, PhD
,
Aditi P. Singh Abramson Cancer Center at the University of Pennsylvania

Search for other papers by Aditi P. Singh in
Current site
Google Scholar
PubMed
Close
 MD
,
Alda Tam The University of Texas MD Anderson Cancer Center

Search for other papers by Alda Tam in
Current site
Google Scholar
PubMed
Close
 MD
,
Tawee Tanvetyanon Moffitt Cancer Center

Search for other papers by Tawee Tanvetyanon in
Current site
Google Scholar
PubMed
Close
 MD, MPH
,
Jane Yanagawa UCLA Jonsson Comprehensive Cancer Center

Search for other papers by Jane Yanagawa in
Current site
Google Scholar
PubMed
Close
 MD
,
Stephen C. Yang The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Search for other papers by Stephen C. Yang in
Current site
Google Scholar
PubMed
Close
 MD
,
Edwin Yau Roswell Park Comprehensive Cancer Center

Search for other papers by Edwin Yau in
Current site
Google Scholar
PubMed
Close
 MD, PhD
,
Kristina Gregory National Comprehensive Cancer Network

Search for other papers by Kristina Gregory in
Current site
Google Scholar
PubMed
Close
 RN, MSN, OCN
, and
Lisa Hang National Comprehensive Cancer Network

Search for other papers by Lisa Hang in
Current site
Google Scholar
PubMed
Close
 PhD
Restricted access

Mesothelioma is a rare cancer that originates from the mesothelial surfaces of the pleura and other sites, and is estimated to occur in approximately 3,500 people in the United States annually. Pleural mesothelioma is the most common type and represents approximately 85% of these cases. The NCCN Guidelines for Mesothelioma: Pleural provide recommendations for the diagnosis, evaluation, treatment, and follow-up for patients with pleural mesothelioma. These NCCN Guidelines Insights highlight significant updates to the NCCN Guidelines for Mesothelioma: Pleural, including revised guidance on disease classification and systemic therapy options.

  • Collapse
  • Expand
  • 1.

    Noone AM, Howlader N, Krapcho M, et al. SEER cancer statistics review (CSR) 1975–2015. Accessed April 1, 2018. Available at: https://seer.cancer.gov/csr/1975_2015/

  • 2.

    American Cancer Society. Special section: rare cancers in adults. Accessed May 1, 2023. Available at: https://tinyurl.com/yb4joe3c

    • PubMed
    • Export Citation
  • 3.

    Price B, Ware A. Time trend of mesothelioma incidence in the United States and projection of future cases: an update based on SEER data for 1973 through 2005. Crit Rev Toxicol 2009;39:576588.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Tsao AS, Wistuba I, Roth JA, et al. Malignant pleural mesothelioma. J Clin Oncol 2009;27:20812090.

  • 5.

    National Cancer Institute. SEER*Explorer: all cancer sites combined, recent trends in SEER age-adjusted incidence rates, 2000–2020. Accessed May 1, 2023. Available at: https://seer.cancer.gov/statistics-network/explorer/

    • PubMed
    • Export Citation
  • 6.

    Grogg JB, Fronzaroli JN, Oliveira P, et al. Clinicopathological characteristics and outcomes in men with mesothelioma of the tunica vaginalis testis: analysis of published case-series data. J Cancer Res Clin Oncol 2021;147:26712679.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Carteni G, Manegold C, Garcia GM, et al. Malignant peritoneal mesothelioma—results from the International Expanded Access program using pemetrexed alone or in combination with a platinum agent. Lung Cancer 2009;64:211218.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Mirarabshahii P, Pillai K, Chua TC, et al. Diffuse malignant peritoneal mesothelioma—an update on treatment. Cancer Treat Rev 2012;38:605612.

  • 9.

    Chekol SS, Sun CC. Malignant mesothelioma of the tunica vaginalis testis: diagnostic studies and differential diagnosis. Arch Pathol Lab Med 2012;136:113117.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Mazurek JM, Syamlal G, Wood JM, et al. Malignant mesothelioma mortality—United States, 1999–2015. MMWR Morb Mortal Wkly Rep 2017;66:214218.

  • 11.

    Meyerhoff RR, Yang CF, Speicher PJ, et al. Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database. J Surg Res 2015;196:2332.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Musk AW, Olsen N, Alfonso H, et al. Predicting survival in malignant mesothelioma. Eur Respir J 2011;38:14201424.

  • 13.

    Linton A, Pavlakis N, O’Connell R, et al. Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales. Br J Cancer 2014;111:18601869.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    Mazurek JM, Blackley DJ, Weissman DN. Malignant mesothelioma mortality in women—United States, 1999–2020. MMWR Morb Mortal Wkly Rep 2022;71:645649.

  • 15.

    Taioli E, Wolf AS, Camacho-Rivera M, et al. Determinants of survival in malignant pleural mesothelioma: a Surveillance, Epidemiology, and End Results (SEER) study of 14,228 patients. PLoS One 2015;10:e0145039.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    Lanphear BP, Buncher CR. Latent period for malignant mesothelioma of occupational origin. J Occup Med 1992;34:718721.

  • 17.

    Selikoff IJ, Hammond EC, Seidman H. Latency of asbestos disease among insulation workers in the United States and Canada. Cancer 1980;46:27362740.

  • 18.

    Sauter JL, Dacic S, Galateau-Salle F, et al. The 2021 WHO Classification of Tumors of the Pleura: advances since the 2015 classification. J Thorac Oncol 2022;17:608622.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19.

    Galateau-Salle F, Churg A, Roggli V, et al. The 2015 World Health Organization Classification of Tumors of the Pleura: advances since the 2004 classification. J Thorac Oncol 2016;11:142154.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20.

    Henderson DW, Reid G, Kao SC, et al. Challenges and controversies in the diagnosis of malignant mesothelioma: part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1 and microRNA. J Clin Pathol 2013;66:854861.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 21.

    Kapeles M, Gensheimer MF, Mart DA, et al. Trimodality treatment of malignant pleural mesothelioma: an institutional review. Am J Clin Oncol 2018;41:3035.

  • 22.

    Nelson DB, Rice DC, Niu J, et al. Long-term survival outcomes of cancer-directed surgery for malignant pleural mesothelioma: propensity score matching analysis. J Clin Oncol 2017;35:33543362.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 23.

    Vogl SE. Guarantee-time bias and benefits of surgery for pleural mesothelioma. J Clin Oncol 2018;36:624625.

  • 24.

    Thieke C, Nicolay NH, Sterzing F, et al. Long-term results in malignant pleural mesothelioma treated with neoadjuvant chemotherapy, extrapleural pneumonectomy and intensity-modulated radiotherapy. Radiat Oncol 2015;10:267.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 25.

    Bölükbas S, Manegold C, Eberlein M, et al. Survival after trimodality therapy for malignant pleural mesothelioma: radical pleurectomy, chemotherapy with cisplatin/pemetrexed and radiotherapy. Lung Cancer 2011;71:7581.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 26.

    de Perrot M, Feld R, Cho BC, et al. Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol 2009;27:14131418.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 27.

    Krug LM, Pass HI, Rusch VW, et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol 2009;27:30073013.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 28.

    Weder W, Stahel RA, Bernhard J, et al. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol 2007;18:11961202.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 29.

    Sugarbaker DJ, Flores RM, Jaklitsch MT, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999;117:5463; discussion 63–65.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 30.

    Lang-Lazdunski L, Bille A, Papa S, et al. Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine, prophylactic radiotherapy, and systemic chemotherapy in patients with malignant pleural mesothelioma: a 10-year experience. J Thorac Cardiovasc Surg 2015;149:558565; discussion 565–566.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 31.

    Lang-Lazdunski L, Bille A, Belcher E, et al. Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine followed by adjuvant chemotherapy in patients with malignant pleural mesothelioma. J Thorac Oncol 2011;6:17461752.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 32.

    Friedberg JS, Culligan MJ, Mick R, et al. Radical pleurectomy and intraoperative photodynamic therapy for malignant pleural mesothelioma. Ann Thorac Surg 2012;93:16581665; discussion 1665–1667.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 33.

    Sugarbaker DJ, Gill RR, Yeap BY, et al. Hyperthermic intraoperative pleural cisplatin chemotherapy extends interval to recurrence and survival among low-risk patients with malignant pleural mesothelioma undergoing surgical macroscopic complete resection. J Thorac Cardiovasc Surg 2013;145:955963.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 34.

    Simone CB 2nd, Cengel KA. Photodynamic therapy for lung cancer and malignant pleural mesothelioma. Semin Oncol 2014;41:820830.

  • 35.

    Du KL, Both S, Friedberg JS, et al. Extrapleural pneumonectomy, photodynamic therapy and intensity modulated radiation therapy for the treatment of malignant pleural mesothelioma. Cancer Biol Ther 2010;10:425429.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 36.

    Ried M, Potzger T, Braune N, et al. Cytoreductive surgery and hyperthermic intrathoracic chemotherapy perfusion for malignant pleural tumours: perioperative management and clinical experience. Eur J Cardiothorac Surg 2013;43:801807.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 37.

    de Bree E, van Ruth S, Baas P, et al. Cytoreductive surgery and intraoperative hyperthermic intrathoracic chemotherapy in patients with malignant pleural mesothelioma or pleural metastases of thymoma. Chest 2002;121:480487.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 38.

    Kotova S, Wong RM, Cameron RB. New and emerging therapeutic options for malignant pleural mesothelioma: review of early clinical trials. Cancer Manag Res 2015;7:5163.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 39.

    Baas P, Scherpereel A, Nowak AK, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet 2021;397:375386.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 40.

    Peters S, Scherpereel A, Cornelissen R, et al. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Ann Oncol 2022;33:488499.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 41.

    Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:26362644.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 42.

    Katirtzoglou N, Gkiozos I, Makrilia N, et al. Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study. Clin Lung Cancer 2010;11:3035.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 43.

    Ceresoli GL, Zucali PA, Favaretto AG, et al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol 2006;24:14431448.

  • 44.

    Castagneto B, Botta M, Aitini E, et al. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). Ann Oncol 2008;19:370373.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 45.

    Santoro A, O’Brien ME, Stahel RA, et al. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program. J Thorac Oncol 2008;3:756763.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 46.

    Zalcman G, Mazieres J, Margery J, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet 2016;387:14051414.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 47.

    Ceresoli GL, Zucali PA, Mencoboni M, et al. Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma. Br J Cancer 2013;109:552558.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 48.

    Kindler HL, Ismaila N, Armato SG 3rd, et al. Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2018;36:13431373.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 49.

    Arrieta O, López-Macías D, Mendoza-García VO, et al. A phase II trial of prolonged, continuous infusion of low-dose gemcitabine plus cisplatin in patients with advanced malignant pleural mesothelioma. Cancer Chemother Pharmacol 2014;73:975982.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 50.

    van Haarst JM, Baas P, Manegold Ch, et al. Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. Br J Cancer 2002;86:342345.

  • 51.

    Nowak AK, Byrne MJ, Williamson R, et al. A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer 2002;87:491496.

  • 52.

    Scagliotti GV, Shin DM, Kindler HL, et al. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol 2003;21:15561561.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 53.

    Taylor P, Castagneto B, Dark G, et al. Single-agent pemetrexed for chemonaïve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program. J Thorac Oncol 2008;3:764771.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 54.

    Muers MF, Stephens RJ, Fisher P, et al. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet 2008;371:16851694.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 55.

    Nishino M, Giobbie-Hurder A, Hatabu H, et al. Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncol 2016;2:16071616.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 56.

    Naidoo J, Wang X, Woo KM, et al. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. J Clin Oncol 2017;35:709717.

  • 57.

    Sgambato A, Casaluce F, Sacco PC, et al. Anti PD-1 and PDL-1 immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC): a review on toxicity profile and its management. Curr Drug Saf 2016;11:6268.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 58.

    Kondola S, Manners D, Nowak AK. Malignant pleural mesothelioma: an update on diagnosis and treatment options. Ther Adv Respir Dis 2016;10:275288.

  • 59.

    Raynaud C, Greillier L, Mazieres J, et al. Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study). BMC Cancer 2015;15:857.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 60.

    Krug LM. An overview of chemotherapy for mesothelioma. Hematol Oncol Clin North Am 2005;19:11171136.

  • 61.

    Abdel-Rahman O, Kelany M. Systemic therapy options for malignant pleural mesothelioma beyond first-line therapy: a systematic review. Expert Rev Respir Med 2015;9:533549.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 62.

    Zauderer MG, Krug LM. Novel therapies in phase II and III trials for malignant pleural mesothelioma. J Natl Compr Canc Netw 2012;10:4247.

  • 63.

    Thomas A, Hassan R. Immunotherapies for non-small-cell lung cancer and mesothelioma. Lancet Oncol 2012;13:e301310.

  • 64.

    Ceresoli GL, Zucali PA, Gianoncelli L, et al. Second-line treatment for malignant pleural mesothelioma. Cancer Treat Rev 2010;36:2432.

  • 65.

    Fennell DA, Ewings S, Ottensmeier C, et al. Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial. Lancet Oncol 2021;22:15301540.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 66.

    Scherpereel A, Mazieres J, Greillier L, et al. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. Lancet Oncol 2019;20:239253.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 67.

    Disselhorst MJ, Quispel-Janssen J, Lalezari F, et al. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial. Lancet Respir Med 2019;7:260270.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 68.

    Scherpereel A, Mazieres J, Greiller L, et al. Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: results of the IFCT-1501 MAPS2 randomized phase 2 trial. J Clin Oncol 2017;35(Suppl):Abstract LBA8507.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 69.

    Zalcman G, Mazieres J, Greillier L, et al. Second or 3rd line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: updated results of the IFCT-1501 MAPS2 randomized phase 2 trial. Ann Oncol 2017;28(Suppl 5):Abstract LBA58.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 70.

    Marcq E, Pauwels P, van Meerbeeck JP, et al. Targeting immune checkpoints: new opportunity for mesothelioma treatment? Cancer Treat Rev 2015;41:914924.

  • 71.

    Jassem J, Ramlau R, Santoro A, et al. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol 2008;26:16981704.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 72.

    Zucali PA, Simonelli M, Michetti G, et al. Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey. Lung Cancer 2012;75:360367.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 73.

    Popat S, Curioni-Fontecedro A, Dafni U, et al. A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial. Ann Oncol 2020;31:17341745.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 74.

    Manegold C, Symanowski J, Gatzemeier U, et al. Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann Oncol 2005;16:923927.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 75.

    Zauderer MG, Kass SL, Woo K, et al. Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma. Lung Cancer 2014;84:271274.

  • 76.

    van Meerbeeck JP, Baas P, Debruyne C, et al. A phase II study of gemcitabine in patients with malignant pleural mesothelioma. Cancer 1999;85:25772582.

  • 77.

    Stebbing J, Powles T, McPherson K, et al. The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. Lung Cancer 2009;63:9497.

  • 78.

    Pinto C, Zucali PA, Pagano M, et al. Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol 2021;22:14381447.

    • PubMed
    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 2157 2158 1823
PDF Downloads 1537 1537 1319
EPUB Downloads 0 0 0